Literature DB >> 29525824

Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.

Raffaella Santi1, Tommaso Cai2, Stefania Nobili3, Ilaria Camilla Galli1, Andrea Amorosi4, Eva Comperat5, Gabriella Nesi6,7.   

Abstract

The current WHO/ISUP classification and grading system subdivides urothelial tumours into prognostically distinct categories. Understanding the molecular pathways involved in bladder cancer development can improve patient stratification and management. This study aims to investigate the relationship between Snail, Slug and E-cadherin expressions and clinico-pathological features of non-muscle invasive bladder carcinoma (NMIBC). All patients attending the same urological centre from January to May 2002, who were pathologically diagnosed with NMIBC, were enrolled in this longitudinal cohort study. E-cadherin, Snail and Slug protein expressions were assessed by immunohistochemical analysis and compared with follow-up data. The main outcome measures were recurrence and progression rates. The cohort under investigation included 43 patients (38 men and 5 women, mean age 67.7 ± 10.6 years). High-grade (HG) carcinomas were 20/43, with 10 invasive cases (pT1). Low-grade (LG) carcinomas were 23/43, with no invasive cases (pTa). Among the eight HGpTa cases with recurrence, strong Snail expression was detected in six (75%). Out of the 17 LGpTa patients who experienced recurrence, 12 (70.6%) showed strong positivity for Snail. Among the 10 HGpT1 cases, recurrence was observed in 4, of which, 3 (75%) stained intensely for Snail. The Kaplan-Meier curves showed significantly different recurrence rates for patients with strong or weak Snail reactivity (p = 0.027). E-cadherin and Slug expression did not correlate with any of the parameters considered. On multivariate analysis, Snail expression was recognised as an independent prognostic factor for tumour recurrence (p = 0.003). In our study population, Snail immunohistochemical overexpression proved to be related to tumour recurrence in patients affected by NMIBC.

Entities:  

Keywords:  Bladder cancer; E-cadherin; Slug; Snail

Mesh:

Substances:

Year:  2018        PMID: 29525824     DOI: 10.1007/s00428-018-2310-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Authors:  Anthony D Yang; Fan Fan; E Ramsay Camp; George van Buren; Wenbiao Liu; Ray Somcio; Michael J Gray; Haiyun Cheng; Paulo M Hoff; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

Review 4.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

5.  Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.

Authors:  Bing Liu; Hideaki Miyake; Masatomo Nishikawa; Masato Fujisawa
Journal:  Urol Oncol       Date:  2014-09-26       Impact factor: 3.498

6.  Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells.

Authors:  Julia Schulte; Michaela Weidig; Philipp Balzer; Petra Richter; Marcus Franz; Kerstin Junker; Mieczyslaw Gajda; Karlheinz Friedrich; Heiko Wunderlich; Arne Östman; Iver Petersen; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2012-07-22       Impact factor: 4.304

7.  Slug Expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Yasuto Uchikado; Shoji Natsugoe; Hiroshi Okumura; Tetsuro Setoyama; Masataka Matsumoto; Sumiya Ishigami; Takashi Aikou
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

8.  A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Authors:  Oliver Patschan; Gottfrid Sjödahl; Gunilla Chebil; Kristina Lövgren; Martin Lauss; Sigurdur Gudjonsson; Petter Kollberg; Pontus Eriksson; Mattias Aine; Wiking Månsson; Mårten Fernö; Fredrik Liedberg; Mattias Höglund
Journal:  Eur Urol       Date:  2015-03-11       Impact factor: 20.096

Review 9.  Natural biology and management of nonmuscle invasive bladder cancer.

Authors:  Kristen R Scarpato; Mark D Tyson; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

Review 10.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

View more
  3 in total

1.  Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.

Authors:  Feng Jin; Muhammad Shahid; Jayoung Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Urinary Markers in Bladder Cancer: An Update.

Authors:  Giorgio Santoni; Maria B Morelli; Consuelo Amantini; Nicola Battelli
Journal:  Front Oncol       Date:  2018-09-07       Impact factor: 6.244

Review 3.  Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.

Authors:  Jayoung Kim; Peng Jin; Wei Yang; Wun Jae Kim
Journal:  Investig Clin Urol       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.